Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFX3772 Compared With PCVs in Healthy Infants
NCT05412030Phase 2Completed
- Sponsor
- GSK
- Start
- Jun 2022
- Primary completion
- Sep 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of AFX3772 in pneumococcal disease (7 arms), sponsored by GSK. Primary endpoints: Number of Participants Reporting Any Solicited Injection Site Adverse Events, Number of Participants Reporting Any Solicited Systemic Events and 2 more. Started Jun 2022; status: completed.
02
Drugs
AFX3772
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT05412030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05412030.